The most promising research
We continuously monitor the most promising Type 1 Diabetes research from around the world. We will carefully evaluate and prioritize the opportunities with the greatest potential to accelerate a cure.
Eledon Pharmaceuticals is developing tegoprubart, a novel immune-modulating therapy designed to help protect transplanted insulin-producing islet cells from immune rejection, while eliminating the toxicities associated with traditional immunosuppressive medications. The goal is to improve long-term success of islet cell transplantation and bring the field closer to a functional cure for Type 1 Diabetes.
NewCelX, in collaboration with Eledon Pharmaceuticals, is developing NCEL-101, a stem cell-derived islet cell therapies combined with Eledon’s novel immune therapy to protect transplanted insulin-producing cells from immune rejection. Their goal is to achieve long-term insulin independence while potentially reducing the need for traditional immunosuppressive drugs, bringing the field closer to a functional cure for Type 1 Diabetes.
Century Therapeutics is developing stem-cell derived islet cell therapies engineered with its Allo-Evasion 5.0 technology, designed to evade the body’s immune system. By combining advanced gene editing with renewable cell sources, the company aims to create an off-the-shelf treatment that could restore natural insulin production without the need for lifelong immunosuppressive drugs, bringing the field closer to a functional cure for Type 1 Diabetes.
Sana Biotechnology is developing engineered stem cell-derived cell therapies engineered with its Hypoimmune HIP technology, designed to evade the body’s immune system without the need for lifelong immunosuppressive drugs. By combining gene-edited insulin-producing cells with advanced immune-evasion technology, Sana aims to create a durable, scalable treatment that could restore natural insulin production and bring the field closer to a functional cure for Type 1 Diabetes.